Head of Regulatory Affairs
Regulatory strategy development, submission management, and global market access for medical device organizations.
Table of Contents
Regulatory Strategy Workflow
Develop regulatory strategy aligned with business objectives and product characteristics.
Workflow: New Product Regulatory Strategy
Gather product information:
Intended use and indications
Device classification (risk level)
Technology platform
Target markets and timeline
Identify applicable regulations per target market:
FDA (US): 21 CFR Part 820, 510(k)/PMA/De Novo
EU: MDR 2017/745, Notified Body requirements
Other markets: Health Canada, PMDA, NMPA, TGA
Determine optimal regulatory pathway:
Compare submission types (510(k) vs De Novo vs PMA)
Assess predicate device availability
Evaluate clinical evidence requirements
Develop regulatory timeline with milestones
Estimate resource requirements and budget
Identify regulatory risks and mitigation strategies
Obtain stakeholder alignment and approval
Validation: Strategy document approved; timeline accepted; resources allocated
Regulatory Pathway Selection Matrix
Factor
510(k)
De Novo
PMA
Predicate Available
Yes
No
N/A
Risk Level
Low-Moderate
Low-Moderate
High
Clinical Data
Usually not required
May be required
Required
Review Time
90 days (MDUFA)
150 days
180 days
User Fee
~$22K (2024)
~$135K
~$440K
Best For
Me-too devices
Novel low-risk
High-risk, novel
Regulatory Strategy Document Template
Copy REGULATORY STRATEGY
Product: [Name]
Version: [X.X]
Date: [Date]
1. PRODUCT OVERVIEW
- Intended use: [Statement]
- Device classification: [Class I/II/III]
- Technology: [Description]
2. TARGET MARKETS
| Market | Priority | Timeline |
|--------|----------|----------|
| USA | 1 | Q1 20XX |
| EU | 2 | Q2 20XX |
3. REGULATORY PATHWAY
- FDA: [510(k) / De Novo / PMA]
- EU: [Class] via [Conformity route]
- Rationale: [Justification]
4. CLINICAL EVIDENCE STRATEGY
- Requirements: [Summary]
- Approach: [Literature / Study / Both]
5. TIMELINE AND MILESTONES
[Gantt or milestone table]
6. RISKS AND MITIGATION
| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
7. RESOURCE REQUIREMENTS
- Budget: $[Amount]
- Personnel: [FTEs]
- External support: [Consultants, CRO]
FDA Submission Workflow
Prepare and submit FDA regulatory applications.
Workflow: 510(k) Submission
Confirm 510(k) pathway suitability:
Predicate device identified
Substantial equivalence supportable
No new intended use or technology concerns
Schedule and conduct Pre-Submission (Q-Sub) meeting if needed
Compile submission package:
Cover letter and administrative information
Device description and intended use
Substantial equivalence comparison
Performance testing data
Biocompatibility (if patient contact)
Software documentation (if applicable)
Labeling and IFU
Conduct internal review and quality check
Prepare eCopy per FDA format requirements
Submit via FDA ESG portal with user fee payment
Monitor MDUFA clock and respond to AI/RTA requests
Validation: Submission accepted; MDUFA date received; tracking system updated
Workflow: PMA Submission
Confirm PMA pathway:
Class III device or no predicate
Clinical data strategy defined
Complete IDE clinical study if required:
IDE approval
Clinical protocol execution
Study report completion
Conduct Pre-Submission meeting
Compile PMA submission:
Administrative and device information
Manufacturing information
Nonclinical studies
Clinical studies
Labeling
Submit original PMA application
Address FDA questions and deficiencies
Prepare for FDA facility inspection
Validation: PMA approved; approval letter received; post-approval requirements documented
FDA Submission Timeline
Milestone
510(k)
De Novo
PMA
Pre-Sub Meeting
Day -90
Day -90
Day -120
Submission
Day 0
Day 0
Day 0
RTA Review
Day 15
Day 15
Day 45
Substantive Review
Days 15-90
Days 15-150
Days 45-180
Decision
Day 90
Day 150
Day 180
Common FDA Deficiencies
Category
Common Issues
Prevention
Substantial Equivalence
Weak predicate comparison
Strong SE argument upfront
Performance Testing
Incomplete test protocols
Follow recognized standards
Biocompatibility
Missing endpoints
ISO 10993 risk assessment
Software
Inadequate documentation
IEC 62304 compliance
Labeling
Inconsistent claims
Early labeling review
See: references/fda-submission-guide.md
EU MDR Submission Workflow
Achieve CE marking under EU MDR 2017/745.
Workflow: MDR Technical Documentation
Confirm device classification per MDR Annex VIII
Select conformity assessment route based on class:
Class I: Self-declaration
Class IIa/IIb: Notified Body involvement
Class III: Full NB assessment
Select and engage Notified Body (for Class IIa+)
Compile Technical Documentation per Annex II:
Device description and specifications
Design and manufacturing information
General Safety and Performance Requirements (GSPR) checklist
Benefit-risk analysis and risk management
Clinical evaluation per Annex XIV
Post-market surveillance plan
Establish and document QMS per ISO 13485
Submit application to Notified Body
Address NB questions and coordinate audit
Validation: CE certificate issued; Declaration of Conformity signed; EUDAMED registration complete
MDR Classification Decision Tree
Copy Is the device active?
│
Yes─┴─No
│ │
▼ ▼
Is it an Does it contact
implant? the body?
│ │
Yes─┴─No Yes─┴─No
│ │ │ │
▼ ▼ ▼ ▼
III IIb Check Class I
contact (measuring/
type sterile if
and applicable)
duration
Clinical Evidence Requirements by Class
Class
Clinical Requirement
Documentation
I
Clinical evaluation (CE)
CE report
IIa
CE with literature focus
CE report + PMCF plan
IIb
CE with clinical data
CE report + PMCF + clinical study (some)
III
CE with clinical investigation
CE report + PMCF + clinical investigation
Notified Body Selection Criteria
Criterion
Consideration
Scope
Device category expertise
Capacity
Availability and review timeline
Experience
Track record in your technology
Geography
Proximity for audits
Cost
Fee structure transparency
Communication
Responsiveness and clarity
See: references/eu-mdr-submission-guide.md
Global Market Access Workflow
Coordinate regulatory approvals across international markets.
Workflow: Multi-Market Submission Strategy
Define target markets based on business priorities
Sequence markets for efficient evidence leverage:
Phase 1: FDA + EU (reference markets)
Phase 2: Recognition markets (Canada, Australia)
Phase 3: Major markets (Japan, China)
Phase 4: Emerging markets
Identify local requirements per market:
Clinical data acceptability
Local agent/representative needs
Language and labeling requirements
Develop master technical file with localization plan
Establish in-country regulatory support
Execute parallel or sequential submissions
Track approvals and coordinate launches
Validation: All target market approvals obtained; registration database updated
Market Priority Matrix
Market
Size
Complexity
Recognition
Priority
USA
Large
High
N/A
1
EU
Large
High
N/A
1-2
Canada
Medium
Medium
MDSAP
2
Australia
Medium
Low
EU accepted
2
Japan
Large
High
Local clinical
3
China
Large
Very High
Local testing
3
Brazil
Medium
High
GMP inspection
3-4
Documentation Efficiency Strategy
Document Type
Single Source
Localization Required
Technical file core
Yes
Format adaptation
Risk management
Yes
None
Clinical data
Yes
Bridging assessment
QMS certificate
Yes (ISO 13485)
Market-specific audit
Labeling
Master label
Translation, local requirements
IFU
Master content
Translation, local symbols
See: references/global-regulatory-pathways.md
Regulatory Intelligence Workflow
Monitor and respond to regulatory changes affecting product portfolio.
Workflow: Regulatory Change Management
Monitor regulatory sources:
FDA Federal Register, guidance documents
EU Official Journal, MDCG guidance
Notified Body communications
Industry associations (AdvaMed, MedTech Europe)
Assess relevance to product portfolio
Evaluate impact:
Timeline to compliance
Resource requirements
Product changes needed
Develop compliance action plan
Communicate to affected stakeholders
Implement required changes
Document compliance status
Validation: Compliance action plan approved; changes implemented on schedule
Regulatory Monitoring Sources
Source
Type
Frequency
FDA Federal Register
Regulations, guidance
Daily
FDA Device Database
510(k), PMA, recalls
Weekly
EU Official Journal
MDR/IVDR updates
Weekly
MDCG Guidance
EU implementation
As published
ISO/IEC
Standards updates
Quarterly
Notified Body
Audit findings, trends
Per interaction
Impact Assessment Template
Copy REGULATORY CHANGE IMPACT ASSESSMENT
Change: [Description]
Source: [Regulation/Guidance]
Effective Date: [Date]
Assessment Date: [Date]
Assessed By: [Name]
AFFECTED PRODUCTS
| Product | Impact | Action Required | Timeline |
|---------|--------|-----------------|----------|
| [Name] | [H/M/L]| [Description] | [Date] |
COMPLIANCE ACTIONS
1. [Action 1] - Owner: [Name] - Due: [Date]
2. [Action 2] - Owner: [Name] - Due: [Date]
RESOURCE REQUIREMENTS
- Budget: $[Amount]
- Personnel: [Hours/FTEs]
APPROVAL
Regulatory: _________________ Date: _______
Management: _________________ Date: _______
Decision Frameworks
Pathway Selection Decision Tree
Copy Is predicate device available?
│
Yes─┴─No
│ │
▼ ▼
Is device Is risk level
substantially Low-Moderate?
equivalent? │
│ Yes─┴─No
Yes─┴─No │ │
│ │ ▼ ▼
▼ ▼ De Novo PMA
510(k) Consider required
De Novo
or PMA
Pre-Submission Meeting Decision
Factor
Schedule Pre-Sub
Skip Pre-Sub
Novel Technology
✓
New Intended Use
✓
Complex Testing
✓
Uncertain Predicate
✓
Clinical Data Needed
✓
Well-established
✓
Clear Predicate
✓
Standard Testing
✓
Regulatory Escalation Criteria
Situation
Escalation Level
Action
Submission rejection
VP Regulatory
Root cause analysis, strategy revision
Major deficiency
Director
Cross-functional response team
Timeline at risk
Management
Resource reallocation review
Regulatory change
VP Regulatory
Portfolio impact assessment
Safety signal
Executive
Immediate containment and reporting
Tools and References
Scripts
Tool
Purpose
Usage
regulatory_tracker.py
Track submission status and timelines
python regulatory_tracker.py
Regulatory Tracker Features:
Track multiple submissions across markets
Monitor status and target dates
Identify overdue submissions
Generate status reports
References
Document
Content
fda-submission-guide.md
FDA pathways, requirements, review process
eu-mdr-submission-guide.md
MDR classification, technical documentation, clinical evidence
global-regulatory-pathways.md
Canada, Japan, China, Australia, Brazil requirements
iso-regulatory-requirements.md
ISO 13485, 14971, 10993, IEC 62304, 62366 requirements
Key Performance Indicators
KPI
Target
Calculation
First-time approval rate
>85%
(Approved without major deficiency / Total submitted) × 100
On-time submission
>90%
(Submitted by target date / Total submissions) × 100
Review cycle compliance
>95%
(Responses within deadline / Total requests) × 100
Regulatory hold time
<20%
(Days on hold / Total review days) × 100
Related Skills